Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

(2018) Lawrence W. Elmer et al.   CNS DRUGS

mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia

(2018) Irene Sebastianutto et al.   CURRENT OPINION IN PHARMACOLOGY

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease

(2018) Tiago Furtado Sampaio et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Animal models of l -dopa-induced dyskinesia in Parkinson's disease

(2018) M. Angela Cenci et al.   MOVEMENT DISORDERS

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

(2018) Susan H. Fox et al.   MOVEMENT DISORDERS

The state of clinical research in neurology

(2018) Deborah A. Hall et al.   NEUROLOGY

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

(2018) Tom H. Johnston et al.   NEUROPHARMACOLOGY

Repurposing drugs to treat l -DOPA-induced dyskinesia in Parkinson's disease

(2018) Tom H. Johnston et al.   NEUROPHARMACOLOGY

Dopamine receptors and BDNF -haplotypes predict dyskinesia in Parkinson's disease

(2018) Cynthia D.J. Kusters et al.   PARKINSONISM & RELATED DISORDERS

Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases

(2018) Carlo Alberto Artusi et al.   PARKINSONISM & RELATED DISORDERS

Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease

(2018) Adolfo Ramirez-Zamora et al.   JAMA Neurology

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease

(2017) Wai Kin D. Ko et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

(2017) Silvia Cerri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Non-human primate models of PD to test novel therapies

(2017) Marc Morissette et al.   JOURNAL OF NEURAL TRANSMISSION

Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia

(2017) Jesper F. Havelund et al.   JOURNAL OF NEUROCHEMISTRY

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

(2017) Jeanne C Latourelle et al.   LANCET NEUROLOGY

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study

(2017) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease

(2017) Susan H. Fox et al.   MOVEMENT DISORDERS

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

(2017) Matej Skorvanek et al.   MOVEMENT DISORDERS

Personalized medicine in Parkinson's disease: Time to be precise

(2017) Nataliya Titova et al.   MOVEMENT DISORDERS

Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias

(2017) Barbara Picconi et al.   MOVEMENT DISORDERS

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias

(2017) Jennifer Stanic et al.   NEUROBIOLOGY OF DISEASE

A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement

(2017) Paul de Roos et al.   Journal of Parkinsons Disease

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

(2017) Rajesh Pahwa et al.   JAMA Neurology

Novel Levodopa Formulations for Parkinson’s Disease

(2016) Maria Eliza Freitas et al.   CNS DRUGS

How close are we to individualized medicine for Parkinson’s disease?

(2016) Hee Jin Kim et al.   Expert Review of Neurotherapeutics

Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies

(2016) Claudia Trenkwalder et al.   MOVEMENT DISORDERS

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

(2016) François Tison et al.   MOVEMENT DISORDERS

Technology in Parkinson's disease: Challenges and opportunities

(2016) Alberto J. Espay et al.   MOVEMENT DISORDERS

l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

(2016) Elaine Del-Bel et al.   SYNAPSE

How close are we to individualized medicine for Parkinson’s disease?

(2016) Hee Jin Kim et al.   Expert Review of Neurotherapeutics

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients

(2015) Rajeev Kumar et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

New treatments for levodopa-induced motor complications

(2015) Olivier Rascol et al.   MOVEMENT DISORDERS

Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease

(2015) Pablo Martinez-Martin et al.   MOVEMENT DISORDERS

International validation of a behavioral scale in Parkinson's disease without dementia

(2015) Isabelle Rieu et al.   MOVEMENT DISORDERS

What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?

(2015) Tiago A. Mestre et al.   PARKINSONISM & RELATED DISORDERS

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression

(2015) Seyed-Mohammad Fereshtehnejad et al.   JAMA Neurology

Pharmacogenetics of drug response in Parkinson's disease

(2014) Eleonora Džoljić et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

(2014) Erwan Bezard et al.   MOVEMENT DISORDERS

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

(2014) Wai Kin D. Ko et al.   MOVEMENT DISORDERS

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease

(2014) Christopher Kobylecki et al.   PARKINSONISM & RELATED DISORDERS

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

(2014) Olivier Rascol et al.   PARKINSONISM & RELATED DISORDERS

Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease

(2014) Nir Giladi et al.   PARKINSONISM & RELATED DISORDERS

Modeling dyskinesia in animal models of Parkinson disease

(2013) Nicolas Morin et al.   EXPERIMENTAL NEUROLOGY

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: Clinical features and mechanisms

(2013) Sara Pietracupa et al.   PARKINSONISM & RELATED DISORDERS

Animal models of l-DOPA–induced dyskinesia: an update on the current options

(2012) H. Iderberg et al.   NEUROSCIENCE

Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials

(2011) Spyridon Spyros Papapetropoulos   CNS Neuroscience & Therapeutics

A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease

(2011) Olivier Rascol et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study

(2010) Fabrizio Stocchi et al.   ANNALS OF NEUROLOGY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap

(2010) Paolo Calabresi et al.   LANCET NEUROLOGY

Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations

(2010) Carlo Colosimo et al.   MOVEMENT DISORDERS

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease

(2010) P. Stathis et al.   MOVEMENT DISORDERS

Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations

(2010) Birgit Högl et al.   MOVEMENT DISORDERS

Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation-Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease

(2009) Marian L. Evatt et al.   MOVEMENT DISORDERS

International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease

(2009) P. Martinez-Martin et al.   NEUROLOGY

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease

(2009) Peter Jenner   PARKINSONISM & RELATED DISORDERS

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Placebo influences on dyskinesia in Parkinson's disease

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease

(2008) Naomi P. Visanji et al.   NEUROBIOLOGY OF DISEASE

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD

(2008) R. Katzenschlager et al.   NEUROLOGY